NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

All NICE products on vulnerable groups. Includes any guidance and quality standards.

There is a simple discount patient access scheme for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...